About Pyrroline-5-carboxylate reductase 1, mitochondrial
Pyrroline-5-carboxylate reductase 1, mitochondrial (PYCR1) is a protein
from Homo sapiens identified by UniProt accession
P32322, 319 residues long.
MolForge cross-references it against 0 known binders and
145 disease associations.
Target properties
| Protein name | Pyrroline-5-carboxylate reductase 1, mitochondrial |
|---|
| UniProt accession | P32322 |
|---|
| Gene | PYCR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 319 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (145)
Diseases linked to this target (Open Targets).
- autosomal recessive cutis laxa type 2B · score 0.83
- PYCR1-related de Barsy syndrome · score 0.77
- cutis laxa · score 0.54
- de Barsy syndrome · score 0.52
- genetic disorder · score 0.52
- geroderma osteodysplastica · score 0.37
- Intellectual disability · score 0.37
- Abnormality of connective tissue · score 0.34
- neurodegenerative disease · score 0.27
- vital capacity · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P32322-F1 | alphafold | PREDICTED | 89.81 | — |
Amino-acid sequence (319 residues)
MSVGFIGAGQ LAFALAKGFT AAGVLAAHKI MASSPDMDLA TVSALRKMGV KLTPHNKETV QHSDVLFLAV KPHIIPFILD EIGADIEDRH IVVSCAAGVT ISSIEKKLSA FRPAPRVIRC MTNTPVVVRE GATVYATGTH AQVEDGRLME QLLSSVGFCT EVEEDLIDAV TGLSGSGPAY AFTALDALAD GGVKMGLPRR LAVRLGAQAL LGAAKMLLHS EQHPGQLKDN VSSPGGATIH ALHVLESGGF RSLLINAVEA SCIRTRELQS MADQEQVSPA AIKKTILDKV KLDSPAGTAL SPSGHTKLLP RSLAPAGKD
Explore Pyrroline-5-carboxylate reductase 1, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets